

Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021

Promore Pharma AB, reg. no. 556639-6809, held its AGM on Thursday, 27 May 2021. The main resolutions passed at the meeting were as follows.

More detailed information about the contents of the resolutions may be obtained from the complete notice of the AGM and the complete proposals. The notice and complete proposals are available on the company's website, www.promorepharma.com.

Adoption of balance sheets and profit and loss accounts

It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2020.

Allocation of result

It was decided that the unappropriated profit of SEK 30,542,480 will be carried forward, in accordance with the Board's proposal.

Discharge from liability

The meeting discharged the directors and the CEO from liability for the financial year 2020.

Directors and auditors

Marianne Dicander Alexandersson, Satyendra Kumar, Göran Linder, Göran Pettersson, and Kerstin Valinder Strinnholm were re-elected and Hans-Peter Ostler was elected as directors. Göran Pettersson was re-elected Chairman of the Board.

The registered audit company Finnhammars Revisionsbyrå AB was re-elected as auditor.

It was decided that the total fees to the directors for the period until the end of the next AGM will amount to SEK 1,000,000, whereof SEK 250,000 to the Chairman of the Board and SEK 150,000 each to the other directors.

Fees will be paid to the auditor on current account.

Board authorisation

It was decided to authorise the Board to, with or without deviation from the shareholders' preferential rights, for the period to the next annual general meeting and on one or several occasions, issue shares, convertibles and warrants, in accordance with the Board's proposal.

The number of shares that the Board shall be entitled to issue, the number of shares that convertibles may entitle to and the number of shares that may be subscribed for on account of warrants, shall totally amount to no more than 7,285,672 new shares, corresponding to a dilution of approximately 20 per cent.

Amendment of the articles of association

It was decided to amend the articles of association, in accordance with the Board's proposal.

Press Release
27 May 2021

For additional information, please contact

Jonas Ekblom, CEO

Phone: [+46] 736 777 540

E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO

Phone: [+46] 708 565 245

E-mail: erik.magnusson@promorepharma.com

Promore Pharms Certified Adviser is Erik Penser Bank

Tel: [+46] 8-463 83 00

E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

[Report from the Annual General Meeting of Promore Pharma AB held on 27 May 2021](#)